Race Oncology Ltd has released a press release.
Race completes over-subscribed $3.159 million placement
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Second Bisantrene Patent Allowed in US
- Notice of Allowance for Bisantrene Patent in US
- Race Receives $170k R&D Tax Incentive Refund
- Race Oncology Produces First Batch of Bisantrene
- Appendix 4E & Annual Financial Statements
Later from Racura Oncology
- Race increases placement to $3.69m
- Race signs global distribution agreement with Durbin PLC
- Race executes agreement for Bisantrene clinical trial
- RAC cancer drug success in AML reported by French doctors
- Bisantrene approval in UK for supply as unlicensed medicine
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology